Ligand Pharma (LGND): Reiterating Sell Despite Upside On Partner Concerns - Deutsche Bank
Deutsche Bank analyst, Esther Rajavelu, reiterated her Sell rating on shares of Ligand Pharma (NASDAQ: LGND) but raised her price ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)